Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 3, 2004, Pages 210-219

  Zhao, Feng ^a,c   Loke, Celine ^a   Rankin, Sheila Clare ^a   Guo, Jia Yi ^a   Lee, How Sung ^b   Wu, Tuck Seng ^a   Tan, Theresa ^b   Liu, Te Chih ^a   Lu, Wan Liang ^a,c   Lim, Yean Teng ^a   Zhang, Qiang ^c   Goh, Boon Cher ^a,b,d   Lee, Soo Chin ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d National University Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

3' UNTRANSLATED REGION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; ETHNOLOGY; EXON; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL STANDARD UNIT; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RNA TRANSLATION;

ADULT; AGED; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENOTYPE; HUMANS; INTRONS; LINKAGE (GENETICS); MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; WARFARIN;

EID: 4544288090     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.05.005     Document Type: Article

References (37)

1. T. Khan, H. Wynne, P. Wood, A. Torrance, C. Hankey, P Avery Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin Br J Haematol 124 2004 348 354
2. E. Shikata, I. Ieiri, S. Ishiguro, H. Aono, K. Inoue, T Koide Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity Blood 103 2004 2630 2635
3. H. Takahashi, H. Echizen Pharmacogenetics of warfarin elimination and its clinical implications Clin Pharmacokinet 40 2001 587 603
4. J. Hirsh, J. Dalen, D.R. Anderson, L. Poller, H. Bussey, J Ansell Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 119 2001 8S 21S
5. CYP2C9 allele nomenclature. Available from: URL: http://www.imm.ki.se/ cypalleles/cyp2c9.htm. Accessed March 1, 2004.
6. F. Peyvandi, M. Spreafico, S.M. Siboni, M. Moia, P.M. Mannucci CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy Clin Pharmacol Ther 75 2004 198 203
7. M. Shintani, I. Ieiri, K. Inoue, K. Mamiya, H. Ninomiya, N Tashiro Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies Clin Pharmacol Ther 70 2001 175 182
8. H. Takahashi, I. Ieiri, G.R. Wilkinson, G. Mayo, T. Kashima, S Kimura 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients Blood 103 2004 3055 3057
9. M. Margaglione, D. Colaizzo, G. D'Andrea, V. Brancaccio, A. Ciampa, E Grandone Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 2000 775 778
10. A.E. Rettie, R.L. Haining, M. Bajpai, R.H. Levy A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin Epilepsy Res 35 1999 253 255
11. A.R. Redman Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing Pharmacotherapy 21 2001 235 242
12. O. Gotoh Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences J Biol Chem 267 1992 83 90
13. P.A. Williams, J. Cosme, A. Ward, H.C. Angove, D. Matak Vinkovic, H. Jhoti Crystal structure of human cytochrome P450 2C9 with bound warfarin Nature 424 2003 464 468
14. H.C. Yu, T.Y. Chan, J.A. Critchley, K.S. Woo Factors determining the maintenance dose of warfarin in Chinese patients QJM 89 1996 127 135
15. Weibert RT, Palinkas LA. Differences in warfarin dose requirements between Asian and Caucasian patients [abstract]. Clin Pharmacol Ther 1991;49:151.
16. H.G. Xie, H.C. Prasad, R.B. Kim, C.M. Stein CYP2C9 allelic variants: ethnic distribution and functional significance Adv Drug Deliv Rev 54 2002 1257 1270
17. G.G. Gan, A. Teh, K.Y. Goh, H.T. Chong, K.W. Pang Racial background is a determinant factor in the maintenance dosage of warfarin Int J Hematol 78 2003 84 86
18. A.Y. Leung, H.C. Chow, Y.L. Kwong, A.K. Lie, A.T. Fung, W.H Chow Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients Blood 98 2001 2584 2587
19. F. Kamali, T.I. Khan, B.P. King, R. Frearson, P. Kesteven, P Wood Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin Clin Pharmacol Ther 75 2004 204 212
20. M. Kimura, I. Ieiri, K. Mamiya, A. Urae, S. Higuchi Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population Ther Drug Monit 20 1998 243 247
21. Y.R. Yoon, J.H. Shon, M.K. Kim, Y.C. Lim, H.R. Lee, J.Y Park Frequency of cytochrome P450 2C9 mutant alleles in a Korean population Br J Clin Pharmacol 51 2001 277 280
22. S.L. Wang, J. Huang, M.D. Lai, J.J. Tsai Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese Pharmacogenetics 5 1995 37 42
23. Z. Zainuddin, L.K. Teh, A.W. Suhaimi, M.Z. Salleh, R. Ismail A simple method for the detection of CYP2C9 polymorphisms: nested allele-specific multiplex polymerase chain reaction Clin Chim Acta 336 2003 97 9102
24. J. Taube, D. Halsall, T. Baglin Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment Blood 96 2000 1816 1819
25. M.W. Linder, S. Looney, I.I.I. Adams JE, N. Johnson, D. Antonino-Green, N Lacefield Warfarin dose adjustments based on CYP2C9 genetic polymorphisms J Thromb Thrombolysis 14 2002 227 232
26. H. Takahashi, T. Kashima, Y. Nomizo, N. Muramoto, T. Shimizu, K Nasu Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes Clin Pharmacol Ther 63 1998 519 528
27. S.M. de Morais, H. Schweikl, J. Blaisdell, J.A. Goldstein Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18 Biochem Biophys Res Commun 194 1993 194 201
28. W. Tang, R.A. Stearns Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions Curr Drug Metab 2 2001 185 198
29. Y. Chen, S.S. Ferguson, M. Negishi, J.A. Goldstein Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor J Pharmacol Exp Ther 308 2004 495 501
30. J. Imai, I. Ieiri, K. Mamiya, S. Miyahara, H. Furuumi, E Nanba Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus Pharmacogenetics 10 2000 85 89
31. R.S. Kidd, T.B. Curry, S. Gallagher, T. Edeki, J. Blaisdell, J.A. Goldstein Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin Pharmacogenetics 11 2001 803 808
32. C. Dandara, C.M. Masimirembwa, A. Magimba, J. Sayi, S. Kaaya, D.K Sommers Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients Eur J Clin Pharmacol 57 2001 11 17
33. L.D. Bradford CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants Pharmacogenomics 3 2002 229 243
34. J.G. Chang No exon 4 polymorphism of cytochrome P450 CYP2C9 in Taiwanese Blood 101 2003 5086 5087
35. A.E. Rettie, G. Tai, D.L. Veenstra, F.M. Farin, S. Srinouanprachan, Y.S Lin CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians Blood 101 2003 2896 2897
36. King BP, Khan T, Kamali F, Daly AK. Novel Cyp2c9 polymorphisms and their relationship to warfarin dose requirements [abstract]. Drug Metab Rev 2003;35:133.
37. Sandberg M, Bloethner S, Malmebo S, Rane A, Johnansson I, Eliasson E. Identification and characterisation of novel SNPs in the 5′-flanking region of the cyp2c9 gene [abstract]. Drug Metab Rev 2003;35:130.